Despite recent approvals, significant unmet need remains in Alzheimer’s market

Despite recent approvals, significant unmet need remains in Alzheimer’s market

Source: 
Clinical Trials Arena
snippet: 

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The current competitive landscape in AD offers medications that are aimed at treating the symptoms of the disease. These drugs are modestly effective and primarily off-patent, creating significant opportunity for new entrants into the AD market.